Analysis
Twelve companies filed S-1 or S-1/A registration statements with the SEC on July 16 and 17, according to EDGAR filings -- a cluster overwhelmingly weighted toward small-cap biotech and biopharma names, including Alpha Modus Holdings, Propanc Biopharma, BioVie, Latigo Biotherapeutics, NuvOx Therapeutics, Valion Bio and Our Bond, alongside amendments from Banzai International, Creatd, Arterior Solutions, Elements Ventures Group and iSpecimen.
The cluster is a useful reminder that the IPO market operating below the mega-cap AI headlines never actually stopped: while SpaceX, Csquare and Standard Nuclear dominate coverage with hundred-billion-dollar valuations and Wall Street price-target wars, dozens of small biotech and biopharma companies continue filing routine registration statements every week, most raising tens of millions rather than billions and drawing little attention outside specialized SEC-filing trackers.
“What to watch next: which of these twelve filers actually price and list in the coming months, and whether any of the S-1/A amendments signal an imminent debut.”
Several of the week's filers -- Banzai International, Creatd and Arterior Solutions among them -- filed S-1/A amendments rather than first-time registrations, indicating companies already further along in the public-offering pipeline continuing to iterate on disclosure language ahead of an eventual pricing, a normal and often lengthy part of the small-cap IPO process that can stretch on for many months between initial filing and actual listing.
The biotech concentration in this particular cluster reflects a sector that's continued going public in a steady drip throughout 2026 even as public biotech valuations remain under pressure broadly, disconnected from the AI-driven mega-cap enthusiasm dominating the rest of the IPO conversation -- a genuinely two-speed public-offering market operating in parallel.
The bear case: most small-cap biotech IPOs in this size range trade poorly post-listing and struggle to maintain liquidity or analyst coverage, and the sheer volume of filings in a single week is itself a sign of an oversaturated micro-cap biotech IPO market rather than a healthy one. What to watch next: which of these twelve filers actually price and list in the coming months, and whether any of the S-1/A amendments signal an imminent debut.
